Clinical trials: Cancer, Carcinoma
Breast Carcinoma
Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer.
- Trial name
- NCT07216274
- Testing
- QT Ultrasound Breast Scanner, Questionnaire Administration
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in treating patients with previously treated prostate cancer that has spread to other areas of the body and does not respond to treatment…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma
- Trial name
- NCT01505868
- Testing
- Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 170 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Adenocarcinoma, Invasive Breast Carcinoma
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
This phase II trial studies how well nab-paclitaxel and atezolizumab before surgery work in treating patients with triple negative breast cancer (breast cancer cells that do not have estrogen receptors, progesterone receptors, or…
- Conditions
- Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
- Trial name
- NCT02530489
- Testing
- Atezolizumab, Nab-paclitaxel
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Carcinoma
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Background: AZD6244 (ARRY-142886) is an investigational anticancer drug that is designed to block a critical component (MEK (methyl ethyl ketone)) of a pathway (MAP (mitogen-activated protein) kinase pathway) that causes some…
- Trial name
- NCT01229150
- Testing
- AZD6244, Erlotinib, AZD6244 + Erlotinib
- Where
- 5 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
This phase III trial studies how well metformin hydrochloride works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT01905046
- Testing
- metformin hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 86 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Thyroid Cancer
A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option…
- Trial name
- NCT00358956
- Testing
- ZD6474 (vandetanib)
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 19 people
- Sponsor
- Genzyme, a Sanofi Company
Renal Cell Carcinoma
PET/MR Characterization of Renal Cell Carcinomas
Purpose: To evaluate the utility of simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) in characterizing the molecular subtypes of clear cell renal cell carcinomas (ccRCC) to potentially inform…
- Trial name
- NCT04271254
- Testing
- PET/MR
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open label, parallel group, Phase II study to evaluate the efficacy and safety of pazopanib compared to sunitinib in Asian subjects with advanced renal cell carcinoma (RCC) who have not received prior…
- Trial name
- NCT01147822
- Testing
- Pazopanib, Sunitinib
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 367 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Some cancers may be related to an infection with a virus, such as the Human Papilloma Virus (HPV). HPV related Oropharyngeal cancer (HPVOPC) accounts for 80% of oropharynx cancer cases in the United States.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT02002182
- Testing
- ADXS11-001 (ADXS-HPV)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Andrew Sikora
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer
This is a Phase IIIb, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with ES-SCLC treated with durvalumab in combination with…
- Trial name
- CANTABRICO (NCT04712903)
- Testing
- Durvalumab, Cisplatin, Etoposide
- Where
- 34 sites in Spain
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head…
- Trial name
- CHANGE2 (NCT02383966)
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-fluorouracil
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
The purpose of this study is to see if a three method risk adapted design using induction chemotherapy, transoral surgery and radiation chemotherapy will lessen toxic effects and make treatment of squamous cell carcinoma of the…
- Trial name
- NCT01612351
- Testing
- Carboplatin, Paclitaxel, Lapatinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer (NSCLC)
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent.
- Trial name
- ARCHER 1042 (NCT01465802)
- Testing
- Dacomitinib, Doxycycline, Probiotic
- Where
- 81 sites in United States, South Korea
- Volunteers
- 236 people
- Sponsor
- Pfizer
Head and Neck Cancer
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for larynx cancer.
- Trial name
- NCT02759575
- Testing
- Pembrolizumab, Radiation Therapy, Cisplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vinita Takiar
Liver Cancer
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00881751
- Testing
- bevacizumab, erlotinib hydrochloride, sorafenib tosylate
- Where
- 6 sites in United States
- Volunteers
- 95 people
- Sponsor
- Medical University of South Carolina
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT03348631
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
- Where
- 581 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in HNSCC With Residual Disease After Radiation
This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy).
- Trial name
- NCT02892201
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Renal Cell Carcinoma
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
Primary Objective: To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b.
- Trial name
- NCT00561912
- Testing
- Decitabine, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
Afatinib Osimertinib Sequencing NIS
This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line…
- Trial name
- NCT03370770
- Testing
- Afatinib, Osimertinib
- Where
- Austria
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.